Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise
News 17.12.2018 Schlieren (Zurich), Switzerland, December 17, 2018 – Kuros Biosciences (SIX: KURN) has completed a transformational year, having realized first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to support the roll-out of MagnetOs, and fund the Phase II clinical trial of fibrinPTH (KUR-113) in spinal...